Tag Archives: ML7710

Treg-Dominant Tumor Microenvironment Is Responsible for Hyperprogressive Disease after PD-1 Blockade Therapy

November 2, 2022 by Modulight Content
No comments
Published in: Cancer Immunology Research Authors: Hiroaki Wakiyama, Takuya Kato, Aki Furusawa, Ryuhei Okada, Fuyuki Inagaki, Hideyuki Furumoto, Hiroshi Fukushima, Shuhei Okuyama, Peter L. Choyke, Hisataka Kobayashi    Published in: Cancer Immunology Research Authors: Hiroaki Wakiyama, Takuya Kato, Aki Furusawa, Ryuhei Okada, Fuyuki Inagaki, Hideyuki Furumoto, Hiroshi Fukushima, Shuhei Okuyama, Peter L. Choyke, Hisataka Kobayashi   Cytotoxic T cells were partially depleted by NIR-PIT (using ML7710 for light activation) in mouse tumor models. PD-1 blockage led to rapid tumor progression compared with controls, indicating that rapid tumor progression, called hyperprogressive disease, after PD-1 blockage therapy can be attributed to imbalance between T cell populations.   Read the article here

Combination of a novel heat shock protein 90-targeted photodynamic therapy with PD-1/PD-L1 blockade induces potent systemic antitumor efficacy and abscopal effect against breast cancers

September 28, 2022 by Modulight Content
No comments
Published in: Journal for ImmunoTherapy of Cancer Authors: Kensuke Kaneko, Chaitanya R Acharya, Hiroshi Nagata, Xiao Yang, Zachary Conrad Hartman, Amy Hobeika, Philip F Hughes, Timothy A J Haystead, Michael A Morse, Herbert Kim Lyerly, Takuya Osada    Published in: Journal for ImmunoTherapy of Cancer Authors: Kensuke Kaneko, Chaitanya R Acharya, Hiroshi Nagata, Xiao Yang, Zachary Conrad Hartman, Amy Hobeika, Philip F Hughes, Timothy A J Haystead, Michael A Morse, Herbert Kim Lyerly, Takuya Osada   Heat shock protein (HS291) targeted PDT was studied in mice with ML7710 to understand immunological component and combination with immune checkpoint inhibitors. The study demonstrates the potential of combined Hsp90-targeted PDT and PD-1/PD-L1 blockade in breast cancer immunotherapy and abscopal effect i.e. efficacy on distal tumors.   Continue reading →

Pharmaceutical nanotechnology applied to phthalocyanines for the promotion of antimicrobial photodynamic therapy: A literature review

September 1, 2022 by Modulight
No comments
Published in: Photodiagnosis and Photodynamic Therapy Authors: Luciana Betzler de Oliveira de Siqueira, Ana Paula dos Santos Matos, Marcio Robert Mattos da Silva, Suvene Rocha Pinto, Ralph Santos-Oliveira, Eduardo Ricci-Júnior  Published in: Photodiagnosis and Photodynamic Therapy Authors: Luciana Betzler de Oliveira de Siqueira, Ana Paula dos Santos Matos, Marcio Robert Mattos da Silva, Suvene Rocha Pinto, Ralph Santos-Oliveira, Eduardo Ricci-Júnior   Phthalocyanines are photosensitizers activated by light at a specific wavelength in the presence of oxygen and act through the production of Reactive Oxygen Species, which simultaneously attack several biomolecular targets in the pathogen agent and, therefore, have multiple and variable action sites. This nonspecific action site bypasses conventional resistance mechanisms. Antimicrobial Photodynamic Therapy (aPDT) is Continue reading →

Fluorescence imaging & endoscopy for tumor visualization and diagnostics

July 6, 2022 by Modulight Content
No comments
Several fluorescent agents have been approved for fluorescence based diagnosis & intraoperative imaging: Dye generic name Countries Excitation Detection Indications Indocyanine Green (ICG) Worldwide 800 nm Near-infrared (820 nm) Multiple uses: lymphatic mapping, tissue perfusion, visualization of biliary ducts and blood veins, retinal angiography Fluorescein Worldwide 490 nm Green fluorescence (525 nm) Fluorescein angiography or angioscopy (ophthalmology) Methylene Blue Worldwide 665 nm 688 nm Endoscopic polypectomy, chromoendoscopy, lymphatic drainage 5-ALA Hydrochloride (converted to Pp-IX) Worldwide 400 – 410 nm Red fluorescence (620 – 710 nm) Continue reading →Introduction to fluorescence imaging Fluorescence is a phenomenon where substance that has absorbed certain wavelength of light emits it back at another wavelength. These substances are called fluorophores or fluorescent dyes. The emitted light has a longer wavelength than the absorbed one since some energy of the photon is lost in the process. The difference in wavelengths between absorbed and emitted light, called Stokes shift, allows very low background for fluorescence detection by separating it from the excitation light. The process of fluorescence generation is Continue reading →

CD29 targeted near-infrared photoimmunotherapy (NIR-PIT) in the treatment of a pigmented melanoma model

January 4, 2022 by Modulight
No comments
Published in: OncoImmunology Authors: Aki Furusawa, Ryuhei Okada, Fuyuki Inagaki, Hiroaki Wakiyama, Takuya Kato, Hideyuki Furumoto, Hiroshi Fukushima, Shuhei Okuyama, Peter L. Choyke, Hisataka Kobayashi    Published in: OncoImmunology Authors: Aki Furusawa, Ryuhei Okada, Fuyuki Inagaki, Hiroaki Wakiyama, Takuya Kato, Hideyuki Furumoto, Hiroshi Fukushima, Shuhei Okuyama, Peter L. Choyke, Hisataka Kobayashi   The study aimed to develop photoimmunotherapy for pigmented melanoma, which can challenging indication since the pigment could absorb light and make treatment ineffective. In vitro & in vivo studies with ML7710 laser compared PIT against pigmented and non-pigmented melanoma and found no differences. CD29 targeted PIT was more effective than CD44 targeted PIT, relating to expression of CD44 on Continue reading →

Light-based enhancement of vaccination in humans

December 20, 2021 by Modulight Content
No comments
  Motivation Vaccines should activate all branches of immunity, including T cells and antibody responses, for generating a strong immune response. For therapeutic cancer vaccines, it is especially important to induce strong cytotoxic T-cell responses, since cytotoxic T-cells are the most potent immune cells for killing cancer cells. While cytotoxic T-cells can often be induced  with viral vector and nucleic acid-based vaccines, peptide-based vaccines often induce only weak cytotoxic T-cell responses . When peptide antigens are taken up into antigen presenting cells, they are generally Continue reading →Customer case PCI Biotech is a biopharmaceutical company located in Norway. They are developing a novel light-based technology called photochemical internalization (PCI) that has potential to enhance delivery and efficacy of many types of therapies, including certain chemotherapies, peptide vaccines, and nucleic acid therapies. It can also decrease side effects due to improved spatiotemporal control of the treatment. The technology is currently in a pivotal clinical study for the treatment of inoperable bile duct cancer where PCI with gemcitabine is combined with standard gemcitabine/cisplatin chemotherapy. Continue reading →

Optimizing photosensitizer administration for cancer therapy

December 11, 2021 by Modulight Content
No comments
  Motivation While Photofrin PDT is an approved oncological therapy for multiple indications, its wider use is hindered by prolonged skin photosensitivity lasting several weeks. The aim of this study is to investigate intratumoral Photofrin administration as a way to decrease skin photosensitivity compared to the standard IV injection protocol. Tumor necrosis after PDT was assessed with immunohistochemical staining and Photofrin distributions by fluorescence microscopy.       Results   Anti-tumor efficacy was similar between intratumoral and IV administration; however, smaller doses of Photofrin were Continue reading →Customer case University of Rochester belongs among the nation’s top research universities. Research at the Baran lab focuses on anti-microbial PDT and optical image processing. The aim is to develop methods for utilizing quantitative information from CT, MR and PET imaging for PDT treatment planning as well as in the search of new biomarkers and therapeutic targets. Modulight products: ML7710 (630 & 665 nm) Link to the study: Timothy M. Baran (Ph.D., PI) Laser use: Ongoing clinical Phase 1 safety & feasibility study for methylene Continue reading →

Optimized light delivery in pancreatic cancer

November 10, 2021 by Modulight Content
No comments
Motivation for the study Efficient light delivery to the whole tumor is one of the main aspects of phototherapy. The efficacy of phototherapy has been demonstrated for several cancers via superficial illumination. Interstitial illumination could enhance light delivery deeper inside the tumor and potentially result in more effective tumor eradication. Hence, the aim of this study is to compare if the therapeutic efficacy of phototherapy is dependent on the light delivery strategies.   Results Phototherapy (PT) with both superficial and interstitial illumination methods efficiently eradicated Continue reading →Customer case University of California at Irvine (UCI), founded in 1965, is a Top 10 public university in USA. It is recognized for cutting-edge and innovative scientific research. Modulight products: ML7710 (689 nm) Laser use: Targeted phototherapy studies with photo-immunoconjugates Link to the study: Nzola De Magalhães, Adjunct Assistant Professor   Motivation for the study Efficient light delivery to the whole tumor is one of the main aspects of phototherapy. The efficacy of phototherapy has been demonstrated for several cancers via superficial illumination. Interstitial illumination could Continue reading →

Modulight Spotlights: LASER-SHARP RESEARCH – September 2021

October 1, 2021 by Modulight Content
No comments
 Modulight Spotlights: LASER-SHARP RESEARCH – September 2021 Laser-Sharp Research nomination goes to this month for Professor Kobayashi’s team and Dr. Noriko Sato’s team at National Cancer Institute, National Institute of Health, USA. Their research published in a prestigious Cancer Research journal showed that photoimmunotherapy can not only target tumor cells, but can also be harnessed to target body’s own tumor-promoting immune cells within the tumor. These special cells called intratumoral Tregs were selectively killed by photoimmunotherapy upon illumination with ML7710 laser, which led to activation Continue reading →

Light delivery optimization for H&N cancer treatment

August 30, 2021 by Modulight Content
No comments
Results Illumination with one fiber Some level of tissue heating was observed at all used light intensities. At lower intensities (60-100 mW/cm), less than 5% of the tumor was subjected to >60 ⁰C temperature, a point where irreversible thermal damage will immediately occur (photothermal ablation). At intensities of 150-200 mW/cm, 15-20% of the tumor was at >60 ⁰C temperature. At 400 mW/cm, which is FDA-recommended light irradiance for iPDT, a substantial portion of the tumor, up to 60%, was above 60 ⁰C.   Above figures Continue reading →Customer case Roswell Park Comprehensive Cancer Center was founded in 1898 as the first institute in the US devoted exclusively to cancer treatment and research. It is also the place where photodynamic therapy (PDT) was developed in the late 1970s by Thomas Dougherty. The PDT center at Roswell Park is a leader in the use of photodynamic therapy for treating different cancers. Research work includes treatment planning and light dosimetry for interstitial and intraoperative PDT to improve the quality of life and survival of cancer patients Continue reading →